ya te digo ke si creoke soltare algo antes del 27

por lo menos para cubrir inversion y con algunas pluses, asi si se hunde pues algo sacas, y si se disapara pues bueno no ganas tanto,pero con un canto en los dientes.

se gana menos pero se preserva el capital bastante bien.

estas farmas son muy puñeteras aplicandolo de esta forma no te forras, pero tampoco te kedas sin capital por una mala jugada

¿Que les pasa a estas dos en esas fechas? el 27 junio en ARNA ¿QUÉ? y el 7 julio en VVUS ¿QUÉ?. Tienen examen en la FDA o algo así. A ver si me podéis informar. Un saludo.

si arna deciden el 27 si la aprueban la suspenden o la retrasan
el de vivus no se si es el 7 de julio,viene d eun retraso de unos meses atras, se supone ke para simplemente hacer unos estudios complementarios, en teoria salvo desatre se supone ke deberian aprobarla, sino no tendria sentido el retraso, pero en fin kien sabe, tambien ha subido bastante ya

hbar ambas estan altas ya, si se aprueban le mercado es muy muy jugoso

pero son farmas ya sabeis, mas peligro ke meter la mano en un saco de escorpiones

lo raro de arna es ke va como un cohete es raro ke no le hayan dado algo los cortos antes de lo del dia 27 mas conla subida ke lleva

en le preaproval por asi decirlo, subio a 6,5 - 7 , y despues de unos dias de titubeo ya ves estamos en 10 casi

a vvus no la llevo la controlo menos, pero tambien tendra margen

Yo creo que este año se verán los 2$. Yo estoy esperando que explote AEZS y lo meto todo en CTIC. y después DSCO. Ese es el orden que yo pienso que pueden explotar. Pero bueno esto tiene que venir con algo de suerte.

Hola bailense, las 2 son farmas por la misma droga, vvus con qnexa y arna con lorcacerin son 2 farmacos para la obesidad .
Para arna la fecha que dio la fda es el 27 de junio.
Para vvus es el 17 de julio.
Ahí se sabrá si el fármaco es ok , no lo es o se piden mas pruebas.
Ambas empresas tuvieron por parte de los asesores de la fda una votación muy f abordable de 18 a 4 o algo asi, esto no significa un 100% de que sea aceptado por la fda pero ayuda,
A partir de ahí cada uno sigue su estrategia, hay mucho movimiento en opciones, mucho mas call que put pero ya sabes todo es seguir la estrategia que mejor se adecua a cada inversor.
Saludos a todos.
Penarolense quien lucha vence.

Alxa, tiene por delante un buen recorrido alcista durante 2 dias.
Alxarce con ella

Si la fda dio el ok a disfrutar de la fiesta......
Felicidades a todos los que estamos, claro me incluyo y ahora sigue vvus.
Pd .mirensen supn

He vendido sunesi y he comprado NANOSPHERE INC

Hola Kemi,

NANOSPHERE INC lleva varios días de subida.

Piensas que seguirá esa tendencia? (a ver ssi me animo)

Suerte

Gnom
hola esto si que es hoy el futuro .
Su precio 10 o 15 us.
Ahora solo 3....
Que les aproveche.

Amigos tras los 2 éxitos consecutivos de arna y vvus ya también aprobada, me retiro a disfrutar una buenas plusvalías
Dejo lo que es pero aun será mejor
Gnom
Hasta setiembre y felicidades para los que también estuvimos en vvus hoy tras algún dime y direte mi capital de vvus viajara.
Saludetes

CPRX cuidadín con ella....!!!!pa meterse ya!!!

Ayer avise CPRX +22%

Una pregunta a los especialistas en farmas, ¿tenemos por ahí alguna buena que se presente para el veredicto de la FDA próximamente?. A ver si podemos sacarles algunos $. Un saludo.

Bueno bueno retomemos los valores.
Gnom, rosg para duplicar gnom en 6 meses y en menos duplica rosg
Saludos

Parece que están un poco paradas las farmas ultimamente, no?. A ver si hay por ahí alguna próxima con noticias como presentación de resultados de ensayos, aprobación de la FDA, etc...

Hola dejo una que es interesante la llevo ya hace unos 3 meses y por ahora viene bien
Es ARIA..
Saludos

Muy buena compra en esta esta tambien uno de los grandes el Sr. Soro

Recs
9

Here's What Smart Billionaire George Soros Is Buying and Selling
By Selena Maranjian | More Articles
May 21, 2012 | Comments (3)

Don't let it get away!
Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.
Click Here Now
Every quarter, many money managers have to disclose what they've bought and sold. Their latest moves can shine a bright light on smart stock picks.

George Soros is known to some folks these days for his politics and philanthropy, but most of his fame stems from his wealth, which is a result of his outstanding investing prowess. He founded Soros Fund Management back in 1973, and under its umbrella, the Quantum funds racked up an amazing record, reportedly averaging close to 20% annual growth over four decades.

As The New York Times has explained, "His huge gains have come from macro bets, which aim to profit from global economic trends by trading currencies, commodities, bonds and other securities. Mr. Soros made his name, however, betting on currencies."

Soros' stock portfolio totaled $6.8 billion in value as of March 31, 2012.

Interesting developments
So what does Soros' latest quarterly 13-F filing tell us? Here are a few interesting details:

New holdings include VIVUS (Nasdaq: VVUS**) and Ariad Pharmaceuticals (Nasdaq: ARIA**) . VIVUS has many investors excited because its anti-obesity drug Qnexa seems close to getting FDA approval, and obesity is a big, fat problem in America and elsewhere. The company also has a drug to treat erectile dysfunction. Ariad has*two promising drugs*that will be reviewed this year -- ridaforolimus tackles sarcomatoid cancer, while ponatinib targets leukemia. (The latter has had some phase 2 trial results that are so promising that it might win early approval from the FDA.)

Among holdings in which Soros increased his stake was networking specialist JDS Uniphase (Nasdaq: JDSU**) . The company was hurt by flooding in Thailand that damaged some of the factories that supplied it, but it has revamped its arrangements and has suffered less than its peers. With its price down from levels at the beginning of the year, the stock is now more attractive.

Soros reduced his stake in lots of companies, including Baidu (Nasdaq: BIDU**) . Some are bearish on the Chinese search-engine giant, as Chinese growth is seen as slowing, but others remain optimistic, since Baidu's slowed growth is still rapid growth, and it still enjoys fat profit margins.

Finally, Soros unloaded several companies, such as Affymax (Nasdaq: AFFY**) . The company's anemia drug Omontys has received FDA approval and could serve many dialysis patients well, but it's also facing competition from Amgen's less convenient Epogen, which many dialysis centers are used to using or have even signed long-term contracts to provide.

We should never blindly copy any investor's moves, no matter how talented the investor. But it can be useful to keep an eye on what smart folks are doing. 13-F forms can be great places to find intriguing candidates for our portfolios.

If you're worried about Baidu and China's shrinking appeal, check out our special free report "3 Stocks to Own for the New Industrial Revolution*," which focuses on a future made in America.

Ditch These ETFs Now
The rumors have been swirling for months: ETFs are dangerous. Now one well-known Motley Fool analyst is going on record to say that your ETF holdings might just sink your portfolio. If you own EEM, EWZ, FXI or any other popular emerging markets ETFs, you should download this FREE investment report. Learn which ETFs to ditch now!

This could be your last, best chance to protect your investments. Learn which ETFs to avoid and WHY today! Download your FREE report now. Simply enter your name below.

This is an advertisement from Motley Fool Asset Management.
Privacy / Legal Information
Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter, holds no position in any company mentioned. Click here to see her holdings and a short bio. The Motley Fool owns shares of Baidu. Motley Fool newsletter services have recommended buying shares of Baidu. The Motley Fool has a disclosure policy.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Genial empresa, brillante gráfico, ya estoy dentro junto al Sr. Soros
Gracias por el dato penalolense

otra recomendacion de compra ahora precio 26 uauuuuuuuuuuuu:

aised its rating on Ariad Pharmaceuticals (NASDAQ: ARIA [FREE Stock Trend Analysis]) from Neutral to Buy and increased its price objective from $20 to $26. Bank of America noted, "Despite ARIA shares +80% YTD performance, we are upgrading from Neutral to Buy based on the favorable risk/reward profile on near term data for ‘113 in lung cancer and subsequent Phase 2 expansion results, as well as our less conservative view of valuation for lead drug PON. While our new PO of $26 (up from $20) does not reflect a large premium to the current stock price, we see 15-70% upside to shares following upcoming lung cancer data (Sept 28-30). The key near term risk to ARIA is negative results for ‘113 ($6/sh of our current valuation), which seems unlikely given trial progress and management's enthusiasm."
Ariad Pharmaceuticals closed at $22.01 on Friday.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Maximize your portfolio - Download the "5 Emerging Markets ETFs: Financial Power For The 21st Century" eBook by Benzinga's ETF Professor HERE.

viene muy bien.
Saludos